UNIVASC Drug Patent Profile
✉ Email this page to a colleague
When do Univasc patents expire, and what generic alternatives are available?
Univasc is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in UNIVASC is moexipril hydrochloride. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the moexipril hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Univasc
A generic version of UNIVASC was approved as moexipril hydrochloride by TEVA on May 8th, 2003.
Summary for UNIVASC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 105 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,970 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in UNIVASC? | UNIVASC excipients list |
| DailyMed Link: | UNIVASC at DailyMed |
Recent Clinical Trials for UNIVASC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Nebraska | Phase 4 |
| Paddock Laboratories, Inc. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for UNIVASC
US Patents and Regulatory Information for UNIVASC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-001 | Apr 19, 1995 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UNIVASC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-001 | Apr 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-001 | Apr 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for UNIVASC
See the table below for patents covering UNIVASC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| German Democratic Republic | 201787 | VERFAHREN ZUR HERSTELLUNG VON SUBSTITUIERTEN ACYLDERIVATEN VON 1,2,3,4-TETRAHYDROISOCHINOLIN-3-CARBONSAEUREN | ⤷ Try a Trial |
| Australia | 1130588 | ⤷ Try a Trial | |
| Israel | 63806 | SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Try a Trial |
| Finland | 881985 | ⤷ Try a Trial | |
| Spain | 505960 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for UNIVASC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0049605 | SPC/GB93/099 | United Kingdom | ⤷ Try a Trial | SPC/GB93/099, EXPIRES: 20040413 |
| 0096157 | SPC/GB95/011 | United Kingdom | ⤷ Try a Trial | SPC/GB95/011:, EXPIRES: 20060930 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
